BioDelivery Technologies

BioDelivery Sciences International (BDSI) is a specialty pharmaceutical company that focuses on developing and commercializing innovative therapies for chronic pain and neurological conditions. The company utilizes its proprietary BioErodible MucoAdhesive (BEMA) technology, which consists of a small, bilayered thin film that adheres to the buccal mucosa and dissolves to deliver medication efficiently into the bloodstream. Its commercial portfolio is headlined by Belbuca for chronic pain and Symproic for opioid-induced constipation. In March 2022, the company was acquired by Collegium Pharmaceutical for approximately $604 million, integrating its pain management assets into Collegium's broader portfolio.